Peptide Radar

FDA July 2026 Peptide Review: what the PCAC meeting covers

PR
Peptide Radar Research Desk
Independent evidence aggregator. Not a clinic, not medical advice. · Updated 2026-07-05 · How we grade evidence
The FDA Pharmacy Compounding Advisory Committee met July 23-24, 2026 to review several peptides nominated for the 503A compounding list. Staff briefing documents proposed NOT adding most of them.

Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.

Vote tracker: all seven peptides

Outcomes will be updated here within hours of each committee vote on July 23-24, 2026. Bookmark this page.

PeptideNominated forFDA staff positionOutcome
Body Protection Compound 157Ulcerative colitis (other referenced uses deemed insufficiently supported)Staff briefing proposed NOT addingPending vote (July 23-24, 2026)
Thymosin beta-4 fragmentWound healing (lyophilized powder for injection)Staff briefing proposed NOT addingPending vote (July 23-24, 2026)
Mitochondrial-derived peptideObesity; osteoporosisStaff briefing proposed NOT addingPending vote (July 23-24, 2026)
Lysine-proline-valine tripeptideWound healing; inflammatory conditions (topical cream/gel)Staff briefing proposed NOT addingPending vote (July 23-24, 2026)
ACTH-fragment heptapeptideCerebral ischemia; migraine; trigeminal neuralgiaStaff briefing proposed NOT addingPending vote (July 23-24, 2026)
EpithalonInsomnia (SC injection)Staff briefing proposed NOT addingPending vote (July 23-24, 2026)
Delta Sleep-Inducing PeptideOpioid withdrawal; chronic insomnia; narcolepsyStaff briefing proposed NOT addingPending vote (July 23-24, 2026)

Why this meeting matters

The PCAC advises the FDA on which bulk substances may be used in compounded medicines. Several performance and longevity peptides were nominated; FDA staff briefing documents proposed not adding most of them, citing gaps in characterization, human safety, and effectiveness.

What 'not added' means

It means the substance is not endorsed for compounded human use through this pathway. It does not make it a supplement, and it does not establish safety or efficacy. Marketing claims implying treatment or recovery remain high-risk.

How to read the coverage

Watch the difference between what was NOMINATED (marketing hopes) and what the FDA staff briefing ACTUALLY supported (usually far less). Evidence grade, not enthusiasm, is the signal.

FAQ

Did the FDA ban these peptides?

The committee reviewed whether to allow them in compounding. 'Not added' is not the same as a formal ban, but it means no endorsement for compounded human use.

Official sources

Get the regulation & evidence watchlist

One email when regulatory status changes or strong new evidence lands. Health topics only. Unsubscribe anytime.

Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.